Dapagliflozin met primary endpoint in DELIVER Phase III trial
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction
Pharmapack Europe recognizes excellence and innovation from exhibitors across connected devices, sustainability, supply chain logistics, route of administration, and packaging innovation, as well from the wider industry for patient-centric design and eco-design
It is developing the drug candidate to potentially treat immunological diseases
GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation Protein Footprinting Systems.
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Support for biologics manufacturability and Industry 4.0 initiatives
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
Subscribe To Our Newsletter & Stay Updated